Table 4.
Univariate and Multivariate Analysis of Clinicopathologic Variables Associated with Overall Survival in 161 Patients with Minor Pathologic Tumor response to Preoperative Chemotherapy for CLM
| Variable | N (%) | 5-year Overall Survival Rate (%) | Univariate Analysis P | Multivariate Analysis* | |
|---|---|---|---|---|---|
| P | Hazard Ratio (95% CI) | ||||
| Sex | 0.458 | ||||
| Male | 90 (56) | 36 | |||
| Female | 71 (44) | 42 | |||
| Age | 0.689 | ||||
| ≥ 60 years | 69 (43) | 40 | |||
| < 60 years | 92 (67) | 37 | |||
| Body mass index | 0.355 | ||||
| > 30 kg/m2 | 53 (33) | 37 | |||
| ≤ 30 kg/m2 | 106 (67) | 40 | |||
| Timing of detection of CLM | 0.202 | ||||
| Synchronous | 95 (59) | 35 | |||
| Metachronous | 66 (41) | 44 | |||
| Primary tumor site | 0.945 | ||||
| Rectum | 53 (33) | 37 | |||
| Colon | 108 (67) | 39 | |||
| Regional lymph nodes for primary tumor | 0.594 | ||||
| Positive | 111 (73) | 39 | |||
| Negative | 50 (29) | 37 | |||
| Preoperative chemotherapy | 0.705 | ||||
| Irinotecan | 84 (52) | 38 | |||
| Oxaliplatin | 77 (48) | 37 | |||
| Preoperative cetuximab | 0.656 | ||||
| Yes | 8 (5) | 63 | |||
| No | 153 (95) | 38 | |||
| Preoperative bevacizumab | 0.938 | ||||
| Yes | 83 (52) | 15 | |||
| No | 78 (48) | 41 | |||
| No. of cycles of chemotherapy | 0.994 | ||||
| ≥ 6 | 97 (60) | 39 | |||
| < 6 | 64 (40) | 38 | |||
| Two-stage hepatectomy | 0.505 | ||||
| Yes | 11 (4) | 44 | |||
| No | 150 (96) | 39 | |||
| Portal vein embolization | 0.438 | ||||
| Yes | 21 (13) | 34 | |||
| No | 140 (87) | 39 | |||
| Associated procedure | 0.442 | ||||
| Yes | 32 (20) | 31 | |||
| No | 129 (80) | 40 | |||
| Major hepatectomy | 0.990 | ||||
| Yes | 110 (68) | 39 | |||
| No | 51 (32) | 40 | |||
| Major postoperative complications | 0.552 | ||||
| Yes | 29 (18) | 38 | |||
| No | 132 (82) | 38 | |||
| Blood transfusion | 0.096 | NS | |||
| Yes | 37 (23) | 33 | |||
| No | 124 (77) | 41 | |||
| Estimated blood loss | 0.569 | ||||
| > 1000 mL | 13 (8) | 39 | |||
| ≤ 1000 mL | 148 (92) | 38 | |||
| Number of CLM | 0.014 | NS | |||
| Multiple | 55 (34) | 32 | |||
| Single | 106 (66) | 52 | |||
| Maximum largest diameter of CLM | 0.039 | NS | |||
| ≥ 3 cm | 101 (63) | 32 | |||
| < 3 cm | 60 (37) | 55 | |||
| Preoperative CEA level | 0.348 | ||||
| ≥ 10 ng/mL | 103 (64) | 33 | |||
| < 10 ng/mL | 58 (36) | 41 | |||
| Margin status for resection of CLM | 0.002 | 0.014 | 2.04 (1.15–3.60) | ||
| R1 | 29 (18) | 0 | |||
| R0 | 132 (82) | 46 | |||
| Postoperative chemotherapy for CLM | 0.859 | ||||
| Yes | 107 (66) | 34 | |||
| No | 54 (34) | 45 | |||
*
Cox regression multivariate analysis included all variables with P < 0.1 in univariate analysis.
CEA indicates carcinoembryonic antigen; CLM, colorectal liver metastases; NS, not significant; R0, surgical margin ≥ 1 mm; R1, no margin or surgical margin < 1 mm.